Trial · NCT05451940
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Hemoglobin (Hb) Response | Baseline to 12 weeks | All enrolled participants who have completed baseline and end of treatment testing, regardless of duration of treatment with EPO, will be included in the analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change in Number of Blood Transfusions Per Year | Baseline to 12 weeks | All enrolled participants who have completed baseline and end-of-treatment (12-week) testing, regardless of duration of treatment with EPO, will be included in the analysis. | Transfusions per year | MEAN |
| OTHER_PRE_SPECIFIED | Changes in Tricuspid Valve Regurgitant Jet Velocity as Assessed by Echocardiography | Baseline to 12 weeks; Baseline to 24 weeks | |||
| OTHER_PRE_SPECIFIED | Changes in Cardiac Index as Assessed by Echocardiography | Baseline to 12 weeks; Baseline to 24 weeks | |||
| OTHER_PRE_SPECIFIED | Changes in Left Ventricular End-diastolic Volume as Assessed by Echocardiography | Baseline to 12 weeks; Baseline to 24 weeks | |||
| OTHER_PRE_SPECIFIED | Changes in Exercise Capacity as Assessed by 6-minute Walk Test With Modified Borg Dyspnea Scale | Baseline to 12 weeks; Baseline to 24 weeks | |||
| OTHER_PRE_SPECIFIED | Changes in Hemoglobin (Hb) | Baseline to 12 weeks | All enrolled participants who have completed baseline and end-of-treatment (12-week) testing, regardless of duration of treatment with EPO, will be included in the analysis. | g/dL | MEAN |
| OTHER_PRE_SPECIFIED | Changes in Absolute Reticulocyte Count | Baseline to 12 weeks; Baseline to 24 weeks | |||
| OTHER_PRE_SPECIFIED | Changes in Lactate Dehydrogenase | Baseline to 12 weeks; Baseline to 24 weeks | |||
| OTHER_PRE_SPECIFIED | Changes in Renal Function | Baseline to 12 weeks; Baseline to 24 weeks | |||
| OTHER_PRE_SPECIFIED | Changes in Urine Albumin-to-creatinine Ratio | Baseline to 12 weeks; Baseline to 24 weeks | |||
| OTHER_PRE_SPECIFIED | Changes in Total and Indirect Bilirubin | Baseline to 12 weeks; Baseline to 24 weeks | |||
| OTHER_PRE_SPECIFIED | Changes in Ferritin | Baseline to 12 weeks; Baseline to 24 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05451940/outcomes